Premium
Jardiance: the latest SGLT2 for the treatment of type 2 diabetes
Author(s) -
Chaplin Steve,
Rajeev Surya,
Wilding John
Publication year - 2015
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1363
Subject(s) - medicine , type 2 diabetes , intensive care medicine , diabetes mellitus , endocrinology
Empagliflozin (Jardiance) is the third SGLT2 inhibitor available for the treatment of type 2 diabetes. Here we present the clinical data relating to its efficacy and adverse events.